Exploring the Benefits of Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers

• In LS carriers, immunotheraphy with NOUS-209 off the shelf vaccine is safe and well tolerated
• NOUS-209 elicits robust neoantigen specific T-cell response in 100% of subjects
• Vaccine-induced responses are broad and recognised multiple neoantigens

Speakers:

Elisa Scarselli

Chief Scientific Officer

Nouscom Srl